Outcome of Board Meeting held on 13th February, 2026 pursuant to Regulation 30 of SEBI(Listing Obligation and Disclosure Requirements)Regulation, 2015
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Boston Commerce Ltd (formerly Boston Bio Systems Ltd) held a board meeting on 13 February 2026 where directors approved the standalone unaudited financial results for the quarter ended 31 December 2025. For Q3 FY26 (Dec 2025), the company reported total income of Rs. 5.85 lakhs but slipped into a loss of Rs. 1.44 lakhs after expenses of Rs. 7.29 lakhs, compared to a profit of Rs. 3.94 lakhs in the previous quarter (Sep 2025). Year-on-year, the loss narrowed sharply from Rs. 5.18 lakhs in Q3 FY25 to Rs. 1.44 lakhs in Q3 FY26. For the nine months ended Dec 2025, the company posted a profit of Rs. 6.51 lakhs on revenue of Rs. 48.37 lakhs, a significant turnaround from a loss of Rs. 5.68 lakhs in the same period last year. The auditor (Sunit M Chhatbar & Co) issued a clean limited review report with no qualifications.
The sequential decline in revenue and return to a small loss in Q3 may concern short-term investors, but the nine-month turnaround from loss to profit signals improving operational performance. Overall, the numbers are positive on a year-on-year basis, though the absolute scale remains very small.